ecrin-mdr-crcClinical2013AnalgesiaVisceral PainPainColorectal cancerColonic DiseasesCancerVisceral PainAnalgesiaPainColorectal CancerColonic DiseasesCancerInterventionalhttps://newmdr.ecrin.org/Study/2150376CanadaUnited States7PreventionHydrogen sulfidePeripheralKappaCRC screeningColonoscopyPain managementColonicTrimebutineOralOpioid agonistSedation-freeECRIN MDRCompletedfalseA Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full ColonoscopyGIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy. It will be evaluated for efficacy and safety in a multi-center, randomized, double-blind, placebo controlled, dose-ranging, proof of concept Phase 2a trial. Up to 240 patients will receive one of 3 doses of GIC-1001 or its matching placebo. A pharmacokinetic evaluation will be carried out on a subset of patients (N: 24).2013-07-152150376NCT01926444